1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Bader, R. Zerbe, O. Beck-Sickinger, A.G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C4 H9 N O2 103.120 n ALPHA-AMINOISOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 275 36043 36048 10.1074/jbc.M000626200 10944518 The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. 2000 10.2210/pdb1fvn/pdb pdb_00001fvn 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4200.611 NEUROPEPTIDE Y I31A, T32(AIB) 1 syn polymer no yes YPSKPDNPGEDAPAEDLARYYSALRHYINLA(AIB)RQRY(NH2) YPSKPDNPGEDAPAEDLARYYSALRHYINLAARQRYX A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list struct_conn struct_ref_seq_dif struct_site repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2000-10-04 1 1 2008-04-27 1 2 2011-07-13 1 3 2021-11-03 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model _struct_conn.pdbx_leaving_atom_flag _struct_ref_seq_dif.details _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id Solution structure of human Neuropeptide Y RCSB Y RCSB 2000-09-20 REL REL The peptide was a designed synthetic molecule. The sequence of the peptide is derived from NPY naturally found in Sus scrofa (pig). sample This structure was determined using standard 2D homonuclear techniques using 200ms NOESY mixing time structures with the lowest energy 100 30 2D NOESY E-COSY 2D NOESY 0 3.1 1 atm 310 K 0 3.1 1 atm 310 K 0 3.1 1 atm 310 K torsion angle dynamics 1 lowest energy 2mM 90% H2O/10% D2O 4mM 90% H2O/10% D2O 2mM 100% D2O Bruker processing XwinNMR 2.1 Bartels & Wuthrich data analysis XEASY 1.53 Guntert & Wuthrich structure solution DYANA 1.5 Guntert & Wuthrich refinement DYANA 1.5 600 Bruker AVANCE TYR 1 n 1 TYR 1 A PRO 2 n 2 PRO 2 A SER 3 n 3 SER 3 A LYS 4 n 4 LYS 4 A PRO 5 n 5 PRO 5 A ASP 6 n 6 ASP 6 A ASN 7 n 7 ASN 7 A PRO 8 n 8 PRO 8 A GLY 9 n 9 GLY 9 A GLU 10 n 10 GLU 10 A ASP 11 n 11 ASP 11 A ALA 12 n 12 ALA 12 A PRO 13 n 13 PRO 13 A ALA 14 n 14 ALA 14 A GLU 15 n 15 GLU 15 A ASP 16 n 16 ASP 16 A LEU 17 n 17 LEU 17 A ALA 18 n 18 ALA 18 A ARG 19 n 19 ARG 19 A TYR 20 n 20 TYR 20 A TYR 21 n 21 TYR 21 A SER 22 n 22 SER 22 A ALA 23 n 23 ALA 23 A LEU 24 n 24 LEU 24 A ARG 25 n 25 ARG 25 A HIS 26 n 26 HIS 26 A TYR 27 n 27 TYR 27 A ILE 28 n 28 ILE 28 A ASN 29 n 29 ASN 29 A LEU 30 n 30 LEU 30 A ALA 31 n 31 ALA 31 A AIB 32 n 32 AIB 32 A ARG 33 n 33 ARG 33 A GLN 34 n 34 GLN 34 A ARG 35 n 35 ARG 35 A TYR 36 n 36 TYR 36 A NH2 237 n 37 NH2 37 A author_defined_assembly 1 monomeric A AIB 32 ALPHA-AMINOISOBUTYRIC ACID A AIB 32 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A O H ILE ALA 28 31 1.54 3 A A O H ILE ALA 28 31 1.54 4 A A O H ILE ALA 28 31 1.52 5 A A O H ILE ALA 28 31 1.56 7 A A O H ILE ALA 28 31 1.55 7 A A O H ALA SER 18 22 1.58 8 A A O H ARG TYR 33 36 1.56 12 A A O H ARG TYR 33 36 1.52 13 A A O H ILE ALA 28 31 1.56 14 A A O H ILE ALA 28 31 1.56 15 A A O HN1 ARG NH2 33 37 1.55 15 A A O H AIB ARG 32 35 1.56 18 A A O H ILE ALA 28 31 1.55 18 A A O H ARG TYR 33 36 1.60 20 A A O H ILE ALA 28 31 1.53 23 A A O H ILE ALA 28 31 1.59 24 A A O H ILE ALA 28 31 1.53 25 A A O H ILE ALA 28 31 1.59 26 A A O H ALA SER 18 22 1.59 29 A A O H ALA SER 18 22 1.58 30 A A O H ALA SER 18 22 1.59 1 A SER 3 63.72 76.23 1 A ASP 6 50.18 95.29 1 A PRO 8 -74.95 -168.44 1 A ASP 11 172.87 115.76 1 A ALA 12 178.45 158.07 1 A ALA 14 83.59 -51.58 1 A ALA 31 -171.20 105.76 1 A AIB 32 -154.47 -38.13 2 A ASP 6 173.59 128.14 2 A ASP 11 53.13 99.21 2 A ALA 14 83.49 -51.58 2 A ARG 33 -146.77 -46.15 3 A SER 3 -67.79 70.11 3 A LYS 4 62.84 142.31 3 A GLU 10 68.30 72.23 3 A ALA 31 -169.95 100.05 3 A AIB 32 -149.94 -37.41 4 A LYS 4 56.16 93.65 4 A ASN 7 169.52 146.76 4 A ASP 11 -141.03 -54.20 4 A PRO 13 -74.97 -168.79 4 A ALA 14 42.62 26.30 4 A ALA 31 -163.77 99.80 4 A AIB 32 -168.67 -33.17 5 A LYS 4 67.80 93.62 5 A ASP 6 65.32 125.81 5 A ASN 7 178.25 150.83 5 A ALA 12 66.75 69.34 5 A GLU 15 -135.05 -34.65 5 A AIB 32 -157.99 -39.16 6 A SER 3 53.51 174.53 6 A ASP 6 55.20 170.93 6 A ASN 7 -40.46 100.71 6 A GLU 10 69.73 65.91 6 A ASP 11 -132.24 -50.41 6 A ALA 12 71.22 67.62 6 A ALA 31 -97.26 37.76 7 A SER 3 63.58 151.73 7 A ASP 6 76.66 118.16 7 A ALA 12 -168.45 75.93 7 A AIB 32 -159.70 -39.63 8 A PRO 2 -75.03 -80.89 8 A SER 3 61.52 110.46 8 A ASP 6 163.59 -35.10 8 A GLU 10 -130.10 -44.40 8 A ALA 12 66.85 154.33 8 A ALA 14 42.53 26.28 8 A ALA 31 -79.49 -96.31 8 A AIB 32 81.43 -25.83 9 A ALA 12 66.59 86.78 9 A ARG 33 -130.61 -42.85 10 A ASP 6 70.17 90.68 10 A ALA 31 -93.78 52.95 10 A ARG 33 -141.69 -46.12 11 A ASP 6 59.72 166.28 11 A ASN 7 41.47 87.86 11 A GLU 10 -104.71 59.16 11 A ASP 11 43.46 84.05 11 A ALA 12 179.13 73.96 12 A ASP 6 59.57 91.96 12 A ASP 11 178.38 161.38 12 A ALA 14 84.05 -50.66 12 A ALA 31 -94.86 49.73 13 A LYS 4 -162.84 93.72 13 A ASP 6 63.94 140.36 13 A ALA 31 -93.41 42.60 14 A SER 3 -165.83 76.01 14 A PRO 5 -75.03 -163.77 14 A ALA 14 83.65 -51.45 14 A ALA 31 -108.64 61.55 15 A SER 3 179.38 -70.87 15 A LYS 4 72.80 157.51 15 A ASN 7 172.95 160.68 15 A GLU 10 39.25 84.57 15 A ASP 11 49.37 94.81 15 A ALA 31 -103.08 51.98 16 A LYS 4 62.84 154.88 16 A ALA 12 169.82 161.90 16 A ALA 14 83.86 -51.19 16 A ALA 31 -90.20 50.77 17 A LYS 4 68.63 93.52 17 A ASN 7 -40.46 100.74 17 A GLU 10 -90.95 56.49 17 A ASP 11 -134.63 -56.04 17 A ALA 12 177.56 154.31 17 A ALA 14 83.70 -51.34 17 A ARG 35 -93.98 30.39 18 A ASP 6 62.07 118.75 18 A ASN 7 162.73 -51.99 18 A ASP 11 57.56 106.60 18 A ALA 14 83.89 -50.93 18 A ALA 31 -79.75 -139.52 18 A AIB 32 83.16 -22.98 19 A PRO 2 -74.98 -88.89 19 A SER 3 39.86 80.32 19 A ASN 7 52.40 94.98 19 A ALA 14 83.62 -51.41 20 A SER 3 -147.05 -58.55 20 A LYS 4 40.56 89.30 20 A ASP 6 59.78 158.28 20 A ASN 7 -174.63 132.64 20 A ASP 11 179.04 87.83 20 A PRO 13 -75.01 -169.72 20 A ALA 14 42.58 26.34 20 A ALA 31 -62.25 -97.71 20 A ARG 33 -151.39 -50.33 20 A ARG 35 -99.90 32.72 21 A SER 3 50.94 -164.33 21 A ASP 11 54.97 171.08 21 A ALA 12 -37.71 98.29 21 A ALA 14 176.07 -40.94 21 A ALA 31 -111.90 54.57 21 A ARG 33 -37.87 -31.29 22 A SER 3 177.93 46.02 22 A ASP 11 -45.92 109.87 23 A SER 3 -174.67 -41.18 23 A LYS 4 165.12 -53.35 23 A ASP 6 -177.08 -56.51 23 A ASN 7 41.85 88.87 23 A ALA 12 -37.66 98.31 23 A ALA 14 176.09 -40.97 23 A AIB 32 -160.16 21.59 23 A ARG 33 -159.92 -45.30 24 A SER 3 74.42 -60.33 24 A ALA 12 -172.72 72.84 24 A ALA 14 176.33 -38.10 24 A ALA 31 -55.49 -97.90 24 A AIB 32 73.26 -1.09 25 A SER 3 176.71 86.73 25 A PRO 5 -75.00 -167.17 25 A ASP 6 -168.01 111.86 25 A GLU 10 -176.10 67.23 25 A ASP 11 67.45 97.16 25 A ALA 14 83.64 -51.41 25 A ARG 33 -134.54 -44.93 25 A ARG 35 -91.27 31.61 26 A LYS 4 53.05 88.84 26 A ALA 12 -157.10 84.97 26 A ALA 31 -85.31 -97.26 26 A AIB 32 82.16 -27.38 26 A GLN 34 -38.75 -29.58 26 A ARG 35 -113.46 58.79 27 A SER 3 -154.60 84.58 27 A LYS 4 56.60 88.96 27 A ASN 7 62.58 132.67 27 A GLU 10 37.50 90.42 27 A ASP 11 174.80 92.66 27 A ALA 31 -106.91 50.76 27 A ARG 33 -141.10 -45.57 27 A ARG 35 -91.07 30.24 28 A SER 3 -152.18 -61.70 28 A LYS 4 71.29 118.39 28 A PRO 5 -74.98 -162.55 28 A GLU 10 69.92 -57.20 28 A ASP 11 -175.17 -83.55 28 A ALA 12 63.48 154.86 28 A ALA 14 42.57 26.31 29 A SER 3 178.15 -71.27 29 A ASP 6 177.24 -54.09 29 A GLU 10 -123.58 -50.75 29 A ARG 33 -132.90 -44.82 29 A ARG 35 -91.01 32.15 30 A SER 3 82.16 -64.31 30 A GLU 10 -130.07 -55.26 30 A ASP 11 48.37 94.66 30 A ALA 12 174.06 165.43 30 A ALA 14 83.75 -51.17 30 A AIB 32 -170.71 -32.81 [ALA31, AIB32]-NEUROPEPTIDE Y 1 N N A ASP 16 A ASP 16 HELX_P A ASN 29 A ASN 29 1 1 14 covale 1.348 both A ALA 31 A C ALA 31 1_555 A AIB 32 A N AIB 32 1_555 covale 1.330 both A AIB 32 A C AIB 32 1_555 A ARG 33 A N ARG 33 1_555 covale 1.325 both A TYR 36 A C TYR 36 1_555 A NH2 37 A N NH2 37 1_555 HORMONE/GROWTH FACTOR alpha, 310-helix, HORMONE-GROWTH FACTOR COMPLEX NEUY_PIG UNP 1 1 P01304 YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY 1 36 1FVN 1 36 P01304 A 1 1 36 1 ILE engineered mutation ALA 31 1FVN A P01304 UNP 31 31 1 THR engineered mutation AIB 32 1FVN A P01304 UNP 32 32 BINDING SITE FOR RESIDUE NH2 A 37 A NH2 37 Software 2 A ARG 33 A ARG 33 2 1_555 A TYR 36 A TYR 36 2 1_555 1 P 1